1520MO Phase I first-in-human study of a novel anti-CD137 switch antibody agonist STA551 (STA) as monotherapy and in combination with atezolizumab (atezo) in patients (pts) with advanced solid tumors.
Saved in:
| Title: | 1520MO Phase I first-in-human study of a novel anti-CD137 switch antibody agonist STA551 (STA) as monotherapy and in combination with atezolizumab (atezo) in patients (pts) with advanced solid tumors. |
|---|---|
| Authors: | Silva, D.1 (AUTHOR), Doi, T.2 (AUTHOR), Koganemaru, S.2 (AUTHOR), Thistlethwaite, F.3 (AUTHOR), Zair, Z.3 (AUTHOR), Yamamoto, N.4 (AUTHOR), Koyama, T.4 (AUTHOR), Inatani, M.5 (AUTHOR), Hashimoto, A.6 (AUTHOR), Takeshita, H.7 (AUTHOR), Takano, Y.8 (AUTHOR), Higashikawa, K.8 (AUTHOR), Ikeda, S.5 (AUTHOR), Tomita, H.9 (AUTHOR), Kanai, Y.5 (AUTHOR), Banerji, U.1 (AUTHOR) |
| Source: | Annals of Oncology. 2025 Supplement 2, Vol. 36, pS911-S912. 2p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2025.08.2151 |
